Completed PHASE4 INTERVENTIONAL 2-arm NCT02060604

Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration

A Randomised Controlled Trial of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration

Sponsor: Università degli Studi di Brescia

Conditions Wet Macular Degeneration

Interventions Ketorolac + Ranibizumab Ranibizumab

Updated 4 times since 2017 Last updated: Feb 8, 2014 Started: Dec 31, 2012 Primary completion: Jan 31, 2014 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Wet Macular Degeneration and is currently completed. Università degli Studi di Brescia leads this study, which shows 4 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2017 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Università degli Studi di Brescia

Data source: Università degli Studi di Brescia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brescia, Italy